Berkeley Eye Center
8
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.4% vs industry average
25%
2 trials in Phase 3/4
83%
5 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Prospective, Randomized, Subject- and Examiner-Masked, Multicenter Study Comparing Bilateral Clareon TruPlus and Bilateral Clareon Monofocal Intraocular Lens Implantation (Spherical and Toric) in Cataract Subjects
Role: lead
Comparison of Two Biometers in Dense Cataracts
Role: lead
Visual Outcomes and Patient Satisfaction With Bilateral PanOptix Verses Bilateral Synergy
Role: lead
Maximizing Visual Outcomes With Eyhance IOLs
Role: lead
Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients
Role: lead
Assessment of Measurement Variability Across Automated Biometry Devices
Role: lead
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
Role: lead
Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs
Role: lead
All 8 trials loaded